Parexel, a CRO providing a full range of Phase I to IV clinical development services, and Partex, a digital pharma platform, entered a strategic alliance designed to leverage artificial intelligence (AI)-powered solutions to accelerate drug discovery and development for biopharmaceutical customers, and to de-risk portfolio assets.
Parexel’s extensive global expertise across Phase I to IV clinical development combined with Partex’s big data and AI capabilities aims to further advance drug development efforts to understand the probability of clinical success of assets in their portfolio and recommend other disease indications for which their assets may be clinically viable.
Clinical trial execution by the Partex group of companies will be managed by Parexel as the preferred CRO provider. The companies will also collaborate on improving clinical trial execution for customers through the Partex-validated AI platform, adding to and expanding Parexel’s existing AI tools and capabilities.
“One of the biggest and most complex challenges in drug development is anticipating the investigational therapies that will be safe and effective treatment options,” said Jamie Macdonald, CEO Parexel. “Our innovative alliance with Partex helps to address this challenge by bringing to the forefront those assets with the strongest probability of clinical success, in turn enabling customers to focus their time and resources where it is most beneficial to patients.”
Gunjan Bhardwaj, CEO Partex said, “By combining Partex’s cutting-edge AI capabilities with Parexel’s renowned clinical research expertise, we aim to accelerate the delivery of safe and effective therapies to patients worldwide, ultimately transforming the biopharmaceutical landscape. We eagerly anticipate the unveiling of new value-generating approaches and groundbreaking innovations resulting from this collaboration.”
